Derma Sciences skins out $36M
December 12, 2012 by MassDevice staff
Derma Sciences raises $36 million closes a $36 million public stock offering it plans to use to continue development on its lead drug candidate for diabetic foot ulcers.
Derma Sciences (NSDQ:DSCI) said it's closed an offering of some 3.5 million shares of its stock at $10.34 apiece.
The Princeton, N.J.-based medical device company said it plans to use the $33.8 million in net proceeds from the $36.4 million offering to further develop its lead drug candidate DSC127.
Derma Sciences said the drug is being designed to treat chronic diabetic foot ulcers.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Mobilizing on the back end of a disaster
- Rising healthcare costs not directly tied to medical technology, according to study
- CareFusion may be weighing 2 very different deals
- Medical Devices: What does it really mean to be disruptive?
- Smarter strategic moves bode well for Wright Medical
- The IRS, NSA, and Justice Department scandals and what they mean for HIPAA
- A Father's Day remembrance
- What I'd tell the graduating medical school class of 2013
- Silencing immune attacks in type 1 diabetes
- Eucomed guidance clarifies RoHS compliance for medical device companies
Navigation
NEWS
Medical device tax: Consultant calls offshoring concerns 'horse hockey'
Concerns that the medical device tax will push companies to lay off workers and move operations...
FDA clears OrthoSensor's Verasense knee replacement device
The FDA clears OrthoSensor's Verasense device, designed to help surgeons fit knee replacement...
ArtVentive Medical wins CE Mark for peripheral catheter
ArtVentive Medical Group wins CE Mark approval in the European Union for its EOS peripheral vascular...
Recalls: FDA makes Endologix catheter introducer recall Class I
The FDA hits Endologix's catheter introducer device recall with Class I status, its most serious...
pSivida gains big on buyout rumor
A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology...
